玛雅吧

中

中文 English

About Us
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
- Company News
- Media Focus
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
Products
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
R&D
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Contact Us
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.



Gainuo (vinorelbine tartrate injection)

vinorelbine tartrate injection

English name: Vinorelbine Tartrate Injection

Chinese Pinyin: Jiushisuan Changchunruibin Zhusheye

The main ingredient of this product is vinorelbine tartrate.

Chemical name: 3',4'-dihydro--4'-deoxy-8'-norvinine ditartrate.

/en/upload/images/2017/10/10/41d2df938ded495a86bfaa0c5ad057da.png

【Name】	Common Name: Vinorelbine Tartrate Injection Brand Name: GAINUO English name: Vinorelbine Tartrate Injection Chinese Pinyin: Jiushisuan Changchunruibin Zhusheye
【Ingredients】	The main ingredient of this product is vinorelbine tartrate. Chemical name: 3',4'-dihydro--4'-deoxy-8'-norvinine ditartrate. Chemical Structure: Molecular formula: C₄₅H₅₄N₄O₈ .2C₄H₆O₆ Molecular weight: 1079.12 Excipients: water for injectio
【Description】	This product is a colorless to yellowish clear liquid.
【Indications】	This product is suitable for patients with non-small cell lung cancer and breast cancer.
【Strength】	1ml:10mg（Calculated on C₄₅H₅₄N₄O₈）.
【Dosage and Administration】	For intravenous use only. Single-Agent: The recommended dose is 25 to 30 mg/m2 weekly. Multidrug therapy:Dosage and dosing time are chosen according to the protocol used. The dose is usually 25 to 30 mg/m2. The drug must be dissolved in physiological saline, intravenously administered in a short period of time (15 to 20 minutes), and then intravenously rinsed with saline.

1999: First-to-market generic drug in China

2002: National Key New Product

2012: Approval (lyophilized powder) from US FDA